Home ›
Entities
› academia
› Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
Research article (American Journal of Hematology, 2021) · cited 57× · AI/ML
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
Summary
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study is a scholarly article[1].
Key Facts
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study. Retrieved May 24, 2026, from https://4ort.xyz/entity/roxadustat-for-the-treatment-of-anemia-in-patients-with-scp-lowerrisk-scp-myelodysplastic-syndrome-openlabel-doseselecti
MLA“Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/roxadustat-for-the-treatment-of-anemia-in-patients-with-scp-lowerrisk-scp-myelodysplastic-syndrome-openlabel-doseselecti.
BibTeX@misc{4ortxyz_roxadustat-for-the-treatment-of-anemia-in-patients-with-scp-lowerrisk-scp-myelodysplastic-syndrome-openlabel-doseselecti_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study}}, year = {2026}, url = {https://4ort.xyz/entity/roxadustat-for-the-treatment-of-anemia-in-patients-with-scp-lowerrisk-scp-myelodysplastic-syndrome-openlabel-doseselecti}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Roxadustat for the treatment of anemia in patients with <scp>lower‐risk</scp> myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study — https://4ort.xyz/entity/roxadustat-for-the-treatment-of-anemia-in-patients-with-scp-lowerrisk-scp-myelodysplastic-syndrome-openlabel-doseselecti (retrieved 2026-05-24)
